Cognito Therapeutics' light-and-sound headset fails Alzheimer's trial
Cognito Therapeutics reported that its Spectris AD device, goggles and headphones worn an hour daily to stimulate gamma brain waves, did not slow cognitive decline in a 673-person trial compared with a sham device. Users of the active device scored nearly 9 points worse on a 156-point cognition and function scale after a year. The company still plans to seek FDA approval next year, citing a subgroup of patients with mild cognitive impairment who appeared to benefit.
GoKawiil's interpretation of the reporting above, not reported fact.
Independent researchers, including Washington University's Eric McDade, called the overall trial result negative and questioned whether a subgroup finding justifies regulatory filing without further study. The outcome could dampen enthusiasm for non-drug, device-based approaches to Alzheimer's treatment, which have drawn attention as alternatives to costly antibody therapies. Whether the FDA accepts subgroup data as sufficient for approval remains uncertain and could set a precedent for similar device trials.
- Spectris AD failed to slow cognitive decline in a 673-patient, year-long randomized trial.
- Cognito Therapeutics points to a mild cognitive impairment subgroup as grounds for an FDA filing next year.
- Outside experts say the overall trial was negative and want further study before any approval.
Source: nature.com — Mullard, 2026-11-17
Published there as: “‘Light and sound’ therapy for Alzheimer’s flops in long-anticipated trial”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.